Skip to content
2000
Volume 22, Issue 1
  • ISSN: 1573-3971
  • E-ISSN: 1875-6360

Abstract

Introduction

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by multisystem involvement due to autoantibody production and immune complex deposition. While classical cutaneous manifestations, such as malar rash, are common, atypical presentations, like periorbital erythema and swelling, are rare and pose diagnostic challenges. Early recognition is crucial to prevent disease progression and complications.

Case Presentation

A 16-year-old girl presented with a three-month history of intermittent bilateral periorbital swelling. Clinical examination revealed pallor and localized alopecia with no significant systemic abnormalities. Laboratory investigations showed pancytopenia with normal renal, hepatic, and thyroid functions and unremarkable urinalysis, chest X-ray, and ECG. Autoimmune markers were positive, with a strongly positive ANA titer of 1:1000 and significantly elevated anti-dsDNA antibodies of 380 IU/mL (reference range: 0-200 IU/mL). According to the 2019 EULAR/ACR classification criteria, a diagnosis of SLE was established. The patient was treated with pulse intravenous methylprednisolone (1g daily for three days), followed by oral prednisolone (1 mg/kg/day), in a tapering regimen and hydroxychloroquine at standard doses. She showed marked improvement, with resolution of periorbital swelling, recovery of pancytopenia, and hair regrowth. At two-month follow-up, she remained asymptomatic and continued hydroxychloroquine for maintenance therapy.

Conclusion

This case underscores the importance of considering SLE in patients with atypical presentations, like periorbital erythema and pancytopenia. Early diagnosis based on clinical and serological findings, followed by appropriate therapy, can achieve remission and prevent complications. The case highlights the need for heightened clinical suspicion and multidisciplinary management in young patients.

Loading

Article metrics loading...

/content/journals/crr/10.2174/0115733971381153250418075039
2025-04-25
2026-03-01
Loading full text...

Full text loading...

References

  1. TsokosG.C. Systemic lupus erythematosus.N. Engl. J. Med.2011365222110212110.1056/NEJMra110035922129255
    [Google Scholar]
  2. KuhnA. RulandV. Cutaneous lupus erythematosus: Insights into pathogenesis and therapeutic strategies.J. Autoimmun.2020110102356
    [Google Scholar]
  3. WuM.Y. WangC.H. NgC.Y. KuoT.T. ChangY.C. YangC.H. LinJ.Y. HoH.C. ChungW.H. ChenC.B. Periorbital erythema and swelling as a presenting sign of lupus erythematosus in tertiary referral centers and literature review.Lupus201827111828183710.1177/096120331879235830134759
    [Google Scholar]
  4. Kasem Ali SlimanR. SaiedH.M. Periorbital edema as the initial manifestation of pediatric systemic lupus erythematosus.Clin. Med. Insights Case Rep.2022151179547622113543010.1177/1179547622113543036339327
    [Google Scholar]
  5. MalaviyaA.N. SinghR.R. KumarA. DeA. KumarA. AradhyeS. Systemic lupus erythematosus in northern India: A review of 329 cases.J. Assoc. Physicians India1988368476480, 4843246502
    [Google Scholar]
  6. AlbrechtJ. BerlinJ.A. BravermanI.M. Dermatology and rheumatology: The spectrum of cutaneous lupus erythematosus.J. Am. Acad. Dermatol.1998386839860
    [Google Scholar]
  7. AkbarianM. KhalkhaliH.R. BavarianR. Neuropsychiatric manifestations of lupus: A review.Lupus20213071050106234152246
    [Google Scholar]
  8. ZahrZ.A. BaerA.N. Hematologic manifestations of systemic lupus erythematosus.Hematol. Oncol. Clin. North Am.2010241165186
    [Google Scholar]
  9. AringerM. CostenbaderK. DaikhD. BrinksR. MoscaM. Ramsey-GoldmanR. SmolenJ.S. WofsyD. BoumpasD.T. KamenD.L. JayneD. CerveraR. Costedoat-ChalumeauN. DiamondB. GladmanD.D. HahnB. HiepeF. JacobsenS. KhannaD. LerstrømK. MassarottiE. McCuneJ. Ruiz-IrastorzaG. Sanchez-GuerreroJ. SchneiderM. UrowitzM. BertsiasG. HoyerB.F. LeuchtenN. TaniC. TedeschiS.K. ToumaZ. SchmajukG. AnicB. AssanF. ChanT.M. ClarkeA.E. CrowM.K. CzirjákL. DoriaA. GraningerW. Halda-KissB. HasniS. IzmirlyP.M. JungM. KumánovicsG. MarietteX. PadjenI. Pego-ReigosaJ.M. Romero-DiazJ. Rúa-Figueroa FernándezÍ. SerorR. StummvollG.H. TanakaY. TektonidouM.G. VasconcelosC. VitalE.M. WallaceD.J. YavuzS. MeroniP.L. FritzlerM.J. NadenR. DörnerT. JohnsonS.R. 2019 European league against rheumatism/american college of rheumatology classification criteria for systemic lupus erythematosus.Arthritis Rheumatol.20197191400141210.1002/art.4093031385462
    [Google Scholar]
  10. VaidyaS. BichileL.S. Systemic lupus erythematosus: Clinical and laboratory profile in Indian patients.J. Postgrad. Med.20034929295
    [Google Scholar]
  11. SinghJ. DinkarA. GuptaP. Uncommon manifestations in tuberculosis: An expanding clinical spectrum from North India.Int. J. Mycobacteriol.2022111303710.4103/ijmy.ijmy_242_2135295021
    [Google Scholar]
  12. SinghJ. DinkarA. GuptaP. AtamV. Vitamin B12 deficiency in northern India tertiary care: Prevalence, risk factors and clinical characteristics.J. Family Med. Prim. Care20221162381238810.4103/jfmpc.jfmpc_650_2136119310
    [Google Scholar]
  13. AlamF. SinghJ. KumarN. KumarK. DinkarA. Massive splenomegaly with pancytopenia in an adult: Gaucher’s disease.Cardiovasc. Hematol. Disord. Drug Targets202323213614010.2174/011871529X25396623092211020237877562
    [Google Scholar]
  14. MakeevaV. Seminario-VidalL. BeckumK. SamiN. Bilateral periorbital swelling as the initial presentation of cutaneous lupus erythematosus.JAAD Case Rep.201621727610.1016/j.jdcr.2015.12.00927051834
    [Google Scholar]
  15. Ruiz-IrastorzaG. Ramos-CasalsM. Brito-ZerónP. KhamashtaM.A. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systematic review.Ann. Rheum. Dis.2010691202810.1136/ard.2008.10176619103632
    [Google Scholar]
  16. FanouriakisA. KostopoulouM. AlunnoA. AringerM. BajemaI. BoletisJ.N. CerveraR. DoriaA. GordonC. GovoniM. HoussiauF. JayneD. KouloumasM. KuhnA. LarsenJ.L. LerstrømK. MoroniG. MoscaM. SchneiderM. SmolenJ.S. SvenungssonE. TesarV. TincaniA. TroldborgA. VollenhovenV.R. WenzelJ. BertsiasG. BoumpasD.T. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.Ann. Rheum. Dis.201978673674510.1136/annrheumdis‑2019‑21508930926722
    [Google Scholar]
  17. NavarraS.V. GuzmánR.M. GallacherA.E. HallS. LevyR.A. JimenezR.E. LiE.K.M. ThomasM. KimH.Y. LeónM.G. TanasescuC. NasonovE. LanJ.L. PinedaL. ZhongZ.J. FreimuthW. PetriM.A. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial.Lancet2011377976772173110.1016/S0140‑6736(10)61354‑221296403
    [Google Scholar]
  18. MorandE.F. FurieR. TanakaY. BruceI.N. AskanaseA.D. RichezC. BaeS.C. BrohawnP.Z. PinedaL. BerglindA. TummalaR. Trial of anifrolumab in active systemic lupus erythematosus.N. Engl. J. Med.2020382321122110.1056/NEJMoa191219631851795
    [Google Scholar]
/content/journals/crr/10.2174/0115733971381153250418075039
Loading
/content/journals/crr/10.2174/0115733971381153250418075039
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test